US EditionGC Biopharma's Recombinant Anthrax Vaccine, BARYTHRAX, Demonstrates Safety and Immunogenicity in Phase 2 Data, Published in 'Vaccine'
- GC Biopharma announced that the Phase 2 clinical trial results of its anthrax vaccine 'BARYTHRAX' were published in the journal Vaccine on Nov. 3, 2025.
- The trial involved 240 healthy adults and demonstrated that BARYTHRAX elicited antibodies exceeding the protective threshold for anthrax toxin.
- Most adverse events reported were mild and temporary, confirming the vaccine's favorable safety profile, with no severe reactions or deaths.
- Experts believe BARYTHRAX could enhance the global response to anthrax and boost national pandemic preparedness as Korea's first recombinant anthrax vaccine.
37 Articles
37 Articles
Rutland Herald
GC Biopharma's Recombinant Anthrax Vaccine, BARYTHRAX, Demonstrates Safety and Immunogenicity in Phase 2 Data, Published in 'Vaccine'
YONGIN, South Korea, Nov. 3, 2025 /PRNewswire/ -- GC Biopharma, a leading global pharmaceutical company based in South Korea, announced today that the Phase 2 clinical trial results for its anthrax vaccine 'BARYTHRAX inj. (GC1109)' have been published in the…
The Committee for Medicinal Products for Veterinary Use (CVMP) of the European Medicines Agency (EMA) has positively evaluated the Biobhyo vaccine designed by the spin-off of the University of León ‘Aquilón Cyl’. It is the first vaccine worldwide against swine dysentery, a highly contagious gastrointestinal disease that causes significant economic losses in the livestock sector. Porcine dysentery affects more than four million animals each year …
Coverage Details
Bias Distribution
- 39% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
